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ORIGINAL STUDIES
THYROID FUNCTION AND DYSFUNCTION
Impact of Hypothyroidism and Heart Failure
on Hospitalization Risk
Kevin Ro,1,2 Alexander D. Yuen,3 Lin Du,4 Clarissa C. Ro,3 Christian Seger,3
Michael W. Yeh,3 Angela M. Leung,1,2 and Connie M. Rhee5
Background: Prior studies suggest that the relationship between hypothyroidism and mortality is dependent on
underlying cardiovascular risk. Little is known about the association of hypothyroidism with hospitalization
risk, and how these associations are modified by cardiovascular status.
Methods: This study examined the association of thyroid status, defined by serum thyrotropin (TSH), with
hospitalization risk among patients who received care at a large university-based tertiary care center between
1990 and 2015. Thyroid status was categorized as hypothyroidism versus euthyroidism (TSH >4.7 vs. 0.3–
4.7mIU/L, respectively). The relationship between thyroid status and hospitalization risk stratified by cardio-
vascular status was examined using multivariable Cox models.
Results: Among 52,856 patients who met eligibility criteria, 49,791 (94.2%) had euthyroidism and 3065 (5.8%)
had hypothyroidism. In analyses stratified by congestive heart failure (CHF) status, compared to euthyroidism,
hypothyroidism was associated with higher risk of hospitalization in those with CHF but slightly lower risk in
those without CHF (adjusted hazard ratio [aHRs]= 1.86 [confidence interval (CI) 1.17–2.94] and HR= 0.95 [CI
0.92–0.99], respectively; p= 0.006). In sensitivity analyses accounting for death as a competing event, un-
derlying coronary artery disease modified the hypothyroidism–hospitalization relationship, such that stronger
associations were observed among those with versus without coronary artery disease. In competing risk ana-
lyses, hypothyroidism was associated with higher versus lower risk of hospitalization among those with versus
without cerebrovascular disease, respectively.
Conclusions: Hypothyroidism is associated with higher hospitalization risk among patients with underlying
cardiovascular disease. Future studies are needed to determine whether correction of thyroid status with re-
placement therapy ameliorates hospitalization risk in this population.
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Introduction
Hypothyroidism is a highly prevalent condition, af-fecting approximately 4–10% of the general population
(1–3). Despite its pervasiveness, prior studies of the associa-
tion between hypothyroidism and hard outcomes such as
hospitalization risk and mortality have yielded conflicting
findings (4–12). Given that hypothyroidism has been associ-
ated with various cardiac derangements (i.e., impaired cardiac
contractility, altered cardiac conduction, increased systemic
vascular resistance, dyslipidemia, accelerated atherosclerosis,
neuro-hormonal activation, and ventricular remodeling), it has
been hypothesized that the relationship between hypothy-
roidism and adverse outcomes may be dependent on an indi-
vidual’s underlying cardiac risk (6,13–15). For example, in a
study of 14,879 participants from the Third National Health
and Nutrition Examination Survey (NHANES III), it was
shown that hypothyroidism was associated with higher mor-
tality in participants with heart failure, but not in those with
normal cardiac status (6). However, little is known about
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whether the inter-relationship between thyroid functional
disease and hospitalization risk may differ according to un-
derlying cardiovascular status.
There has also been increasing interest in whether race and
ethnicity may modify the association of hypothyroidism and
outcomes (6,16). Large population-based studies in the
United States have shown that both non-Hispanic black and
Hispanic populations have lower median thyrotropin (TSH)
levels than non-Hispanic whites, suggesting that there may be
different physiologic set points for thyroid status according to
race/ethnicity (2). While one study has shown that hypothy-
roidism is associated with higher mortality risk in black
participants versus those of other racial backgrounds, there
remains a paucity of data examining whether there is a dif-
ferential relationship between thyroid dysfunction and out-
comes across race and ethnicity (6).
Thus, to better inform the field, a study was conducted to
examine whether the association between hypothyroidism
and hospitalization risk is modified by (i) underlying car-
diovascular status and (ii) race/ethnicity among a racially and
ethnically diverse cohort of patients receiving care from a
large university-based tertiary care center with detailed lab-
oratory data and extended follow-up over which to observe
outcomes.
Methods
Source cohort
A historical cohort study was conducted utilizing data from
the University of California Los Angeles (UCLA) Health
System electronic medical records with detailed patient-
level information on socio-demographics, comorbidities, lab-
oratory tests, and clinical events, including hospitalizations.
Patients were included in the study provided that they under-
went a serum TSH measurement over the period January 1,
1990–March 30, 2015, were aged ‡18 years at the time of
baseline serum TSH measurement, and had available race
and ethnicity data. The study was approved by the UCLA
Institutional Review Committee.
In total, 54,340 patients met the aforementioned criteria
with follow-up data. Given that the primary subject of interest
was the examination of hypothyroidism versus euthyroidism
with hospitalization risk, patients with hyperthyroidism—
defined as baseline serum TSH levels less than the lower limit
of the normal reference range (TSH <0.3mIU/L)—were
excluded (n = 1484). After exclusions, 52,856 patients re-
mained in the final analytic cohort.
Exposure ascertainment
The exposure of interest was thyroid status defined by
baseline serum TSH level. The study sought to examine the
association between baseline thyroid status and hospitaliza-
tion risk, and how these associations are modified by car-
diovascular status and race/ethnicity. Patients with TSH
levels within the assay reference range (TSH 0.3–4.7mIU/L)
were considered euthyroid, whereas patients with TSH levels
higher than the upper limit of the normal reference range
were considered hypothyroid (TSH >4.7mIU/L). The same
TSH assay was used for the duration of the study. Patients
receiving thyroid hormone supplementation or antithyroid
therapy were categorized according to their baseline TSH
level, as a patient with a high TSH level despite receipt of
thyroid hormone supplementation was considered to be
biochemically hypothyroid.
Outcome ascertainment
The primary outcome of interest was all-cause hospitali-
zation, which was defined as a composite of both inpatient
hospital admissions and/or emergency room visits within the
UCLA Medical Centers. At-risk time began the day after the
baseline TSH measurement. Patients were censored for death
or at the end of the study period (March 30, 2015).
Comorbidities, race, and ethnicity
Comorbidities were defined using the International Clas-
sification of Diseases ninth revision (ICD-9) codes for con-
gestive heart failure (CHF), coronary artery disease (CAD),
cerebrovascular disease (CVD), diabetes, hypertension, and
hyperlipidemia (Supplementary Table S1; Supplementary
Data are available online at www.liebertpub.com/thy). Race/
ethnicity data were self-reported. Race was categorized as
white, black, Asian, or other. Ethnicity was categorized as
Hispanic versus non-Hispanic.
Statistical analysis
Baseline characteristics of patients according to thyroid
status were compared using two-sample t-tests, Wilcoxon rank
sum tests, and chi-square tests according to data type. The
associations between thyroid status and hospitalization risk
were estimated using multivariable Cox proportional hazards
models adjusted for age, sex, race, ethnicity, body mass index,
diabetes, hypertension, hyperlipidemia, CHF, CAD, and CVD
(17,18). The proportional hazards assumption was confirmed
graphically and through Schoenfeld residual testing.
To determine whether the association of thyroid status and
hospitalization risk is modified by cardiovascular status, sub-
group analyses were conducted across categories of baseline
CHF, CAD, CVD, and cardiovascular medication use (Sup-
plementary Table 2). In secondary analyses, the association
of thyroid status and hospitalization risk was then exam-
ined across subgroups of race (white, black, Asian, other)
and ethnicity (Hispanic vs. non-Hispanic). Statistical signifi-
cance of subgroup analyses was assessed by likelihood ratio
testing comparing models with and without the corresponding
two-way factor-by-exposure cross-product terms (e.g., CHF·
hypothyroidism). An p-value of <0.05 was considered statis-
tically significant.
Given that thyroid status has been associated with higher
death risk in prior studies (5), mortality may be a competing
risk such that a death event hinders the observation of the event
of interest (e.g., hospitalization risk) or alters the likelihood
that this event occurs (19). Given that standard Cox regression
analyses do not account for competing risks, sensitivity ana-
lyses were also conducted using the cumulative incidence
function. Maximum likelihood estimates of the regression
coefficients were obtained by the Newton–Raphson algorithm.
Due to the bias in the Kaplan–Meier method of estimating the
survivor function with competing risk cases, the cumulative
incidence function (20) was introduced to handle the marginal
failure sub-distribution of a given cause. In SAS v9.4 (SAS
Institute, Inc., Cary, NC), PROCPHREGwas performed in the
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subgroup analysis by specifying the EVENTCODE= option in
the MODEL statement. To specify the maximum likelihood
estimates of coefficients, PROC PHREG was implemented
with the Newton–Raphson algorithm (21). There were no
missing covariate data for the multivariable analyses, includ-
ing age, sex, race, ethnicity, comorbidities, and medication
use. This study was conducted under STROBE guidelines.
Results
Study population
Among 52,856 patients who met eligibility criteria (Sup-
plementary Fig. S1), 49,791 (94.2%) were euthyroid and
3065 (5.8%) were hypothyroid. The baseline characteristics
of the cohort are shown in Table 1. Compared to euthyroid
patients, hypothyroid patients tended to be of older age, fe-
male sex, white race, and Hispanic ethnicity. Hypothyroid
patients also had higher prevalence of diabetes and greater
use of thyroid hormone supplementation as well as antithy-
roid medication. The median (IQR) andminimum–maximum
values of TSH in the euthyroid group were 1.7mIU/L (1.2–
2.4mIU/L) and 0.3–4.68mIU/L, respectively. The median
(IQR) and minimum–maximum values of TSH in the hypo-
thyroid group were 6.0mIU/L (5.1–8.2mIU/L) and 4.7–
204.0mIU/L, respectively.
Hypothyroidism and hospitalization risk according
to underlying cardiovascular status
Among the overall cohort, there were a total of 13,023
hospitalization events (Supplementary Table S3), and the
median (IQR) follow-up period was 5.61 years (2.63–8.78
years). In adjusted analyses, underlying CHF status was
found to modify the association between hypothyroidism
and hospitalization risk ( p = 0.006; Fig. 1 and Table 2). In
patients with CHF, hypothyroidism was associated with a
significantly higher risk of hospitalization (reference: eu-
thyroidism): adjusted hazard ratio (aHR) = 1.86 [confidence
interval (CI) 1.17–2.94]. However, among those without
CHF, hypothyroidism was associated with a slightly lower
risk of hospitalization (aHR = 0.95 [CI 0.92–0.99]).
The study also examined whether other preexisting car-
diovascular diseases modified the association between hy-
pothyroidism and hospitalization risk in adjusted analyses
(Table 2). There did not appear to be effect modification of
the association between hypothyroidism and hospitalization
risk according to underlying CAD status ( p= 0.81). In ana-
lyses stratified by CVD status, there appeared to be a trend
toward an association between hypothyroidism and lower
risk of hospitalization among those without underlying CVD
(aHR = 0.84 [CI 0.59–1.18]) but not in those with CVD
(aHR = 0.96 [CI 0.92–0.99]). However, interaction testing
did not show statistical significance ( p = 0.56), indicating that
these differences were no more than what was explained by
chance. Similarly, in analyses stratified by cardiovascular
medication use, there appeared to be an association between
hypothyroidism and lower risk of hospitalization among
those without medication use (aHR = 0.96 [CI 0.92–0.99])
but not in those with medication use (aHR = 1.05 [CI 0.81–
1.34]). However, interaction testing did not show statistical
significance ( p = 0.43), indicating that these differences were
no more than what is explained by chance.
Table 1. Baseline Characteristics According
to Thyroid Functional Status
Euthyroid
(n= 49,791)
Hypothyroid
(n= 3065) p-Value
TSH, mIU/L
Median 1.7 6.0 <0.001
IQR 1.2–2.4 5.1–8.2
Min–max 0.3–4.7 4.7–204.0
Age (years), M – SD 52– 17 57– 1 <0.001
Sex, %
Male 36 34 <0.001
Female 64 67
BMI (kg/m2), M– SD 26.6 – 6.0 26.8– 6.3 = 0.04
Race, %
White 76 82 <0.001
Black 9 5
Asian 13 12
Other 2 2
Ethnicity, %
Hispanic 9 11 <0.001
Non-Hispanic 92 89
Diabetes, %
Yes 4 6 <0.001
No 96 94
Hypertension, %
Yes 3 3 = 0.55
No 98 97
Hyperlipidemia, %
Yes 2 1 = 0.20
No 98 99
CHF, %
Yes 0.7 0.8 = 0.37
No 99.3 99.2
CAD, %
Yes 0.6 0.7 = 0.68
No 99.4 99.3
CVD, %
Yes 1.1 1.7 = 0.003
No 98.9 98.3
AFib, %
Yes 1.48 2.87 <0.001
No 98.52 97.73
Thyroid hormone
supplementation
use, %
Yes 5.5 20.4 <0.001
No 94.5 79.6
Antithyroid medication
use, %
Yes 0.1 0.4 = 0.01
No 99.9 99.6
Prior history of thyroid
disease, %
Yes 0.83 4.21 <0.001
No 99.17 95.79
Prior thyroidectomy/
RAI ablation, %
Yes 0.61 1.86 <0.001
No 99.39 98.14
TSH, thyrotropin; IQR, interquartile range; SD, standard devia-
tion; BMI, body mass index; CHF, congestive heart failure; CAD,
coronary artery disease; CVD, cerebrovascular disease; AFib, atrial
fibrillation; RAI, radioactive iodine.
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Hypothyroidism and hospitalization risk according
to sociodemographic characteristics
The study also examined whether patients’ socio-
demographic characteristics modified the association be-
tween hypothyroidism and hospitalization risk in adjusted
analyses (Table 3). It was found that age modified the asso-
ciation between hypothyroidism and hospitalization risk
( p < 0.001). In younger patients (aged <60 years), hypothy-
roidism was associated with a significantly lower risk of
hospitalization (aHR = 0.89 [CI 0.85–0.94]). In older patients
(aged ‡60 years), there was a trend toward an association
between hypothyroidism and higher hospitalization risk, al-
though this did not reach statistical significance (aHR = 1.05
[CI 0.99–1.11]).
In analyses stratified by sex, while there appeared to be a
trend toward an association between hypothyroidism and
lower risk of hospitalization among female patients (aHR =
0.94 [CI 0.90–0.99]) but not in male patients (aHR = 0.99 [CI
0.93–1.06]). However, interaction testing did not show sta-
tistical significance ( p= 0.28). Similarly, in analyses strati-
fied by race, while there appeared to be a trend toward an
association between hypothyroidism and lower risk of hos-
pitalization among non-black patients (aHR = 0.96 [CI 0.92–
1.00]) but not in black patients (aHR = 0.89 [CI 0.5–1.07]),
interaction testing did not show statistical significance
( p= 0.57). Finally, in analyses stratified by ethnicity, while
there appeared to be a trend toward an association between
hypothyroidism and lower risk of hospitalization among non-
Hispanic patients (aHR = 0.96 [CI 0.92–1.00]) but not in
Hispanic patients (aHR = 0.96 [CI 0.85–1.09]), interaction
testing did not show statistical significance ( p = 0.83).
Competing risk analyses
Sensitivity analyses were also conducted of the association
between hypothyroidism and hospitalization risk stratified by
underlying cardiovascular disease status in which all-cause
death was accounted for as a competing risk. Similar to the
primary analyses, when strata of CHF status were examined,
there was an association between hypothyroidism and higher
risk of hospitalization among those with underlying CHF
(aHR = 2.26 [CI 1.77–2.75]) but not among those without
CHF (aHR = 1.06 [CI 0.92–1.23]), although interaction test-
ing narrowly missed statistical significance ( p = 0.07). In
contrast to the primary analyses, it was found that preexisting
CAD modified the association between hypothyroidism and
hospitalization risk such that point estimates of the hypo-
thyroidism–hospitalization risk association were even
stronger among those with CAD (aHR = 3.32 [CI 3.21–3.50])
versus those without CAD (aHR = 1.20 [CI 1.02–1.38];
p < 0.001). It was also found that underlying CVD modified
the association between hypothyroidism and hospitalization
risk such that hypothyroidism was associated with higher risk
of hospitalization among those with CVD (aHR = 1.98 [CI
1.79–2.16]) and lower risk among those without CVD
(aHR = 0.68 [CI 0.50–0.87]; p < 0.001). Finally, it was also
FIG. 1. Hypothyroidism and hospitalization among patients
with versus without congestive heart failure (CHF). Analyses
adjusted for age, sex, race, ethnicity, body mass index, dia-
betes, hypertension, hyperlipidemia, CHF, coronary artery
disease, and cerebrovascular disease.
Table 2. Association Between Hypothyroidism with Hospitalization Risk,
Stratified by Underlying Cardiovascular Disease Status
# of
events
Risk
time
Unadjusted Adjusted
Adjusted (including
amiodarone)
HR [CI] p HR [CI] p HR [CI] p
CHF
Yes 124 3.75 1.22 [1.02–1.43] 0.001 1.86 [1.17–2.94] 0.006 1.23 [1.08–1.39] 0.002
No 12899 4.77 0.82 [0.72–0.92] 0.95 [0.92–0.99] 0.87 [0.65–1.02]
CAD
Yes 144 4.31 1.41 [1.28–1.68] 0.53 1.08 [0.61–1.89] 0.81 1.07 [0.74–1.38] 0.62
No 12879 4.76 0.73 [0.64–0.84] 0.96 [0.92–0.99] 0.93 [0.86–1.16]
CVD
Yes 202 4.14 1.15 [1.01–1.31] 0.24 0.84 [0.59–1.18] 0.56 0.91 [0.72–1.26] 0.39
No 12821 4.77 0.9 [0.82–0.99] 0.96 [0.92–1.00] 1.11 [1.0–1.22]
Cardiovascular medication use
Yes 184 3.73 1.16 [0.98–1.41] 0.39 1.05 [0.81–1.34] 0.43 1.13 [1.03–1.24] 0.11
No 7993 4.78 0.89 [0.81–0.97] 0.96 [0.92–0.99] 0.89 [0.69–1.09]
Analyses adjusted for age, sex, race, ethnicity, body mass index, diabetes, hypertension, hyperlipidemia, CHF, CAD, and CVD.
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observed that cardiovascular medication use modified the
association between hypothyroidism and hospitalization risk
such that hypothyroidism was associated with lower risk of
hospitalization among those without medication use (aHR =
0.96 [CI 0.92–0.99]) but not in those with medication use
(aHR = 1.05 [CI 0.81–1.34]; p= 0.04).
Discussion
In a large, racially/ethnically diverse cohort of patients
receiving care at a large university-based academic center, it
was found that underlying cardiovascular status was a potent
modifier of the association between hypothyroidism and risk
of hospitalization. In the primary analyses, it was found that
compared to euthyroid status, hypothyroidismwas associated
with a 1.9-fold higher risk of hospitalization among those
with CHF and a slightly lower risk of hospitalization among
those without CHF. In sensitivity analyses that accounted for
death as a competing risk, it was additionally found that
hypothyroidism had an even stronger association with hos-
pitalization risk among those with versus without CAD (3.3-
vs. 1.2-fold higher risk, respectively). It was also found that
hypothyroidism was associated with a nearly twofold higher
risk of hospitalization among those with CVD, but slightly
lower risk among those without CVD. These associations
were observed independent of confounders such as socio-
demographic characteristics, comorbidity burden, and body
mass index.
To the authors’ knowledge, this is the first large, population-
based study to examine whether hypothyroidism is associated
with hospitalization risk according to underlying cardiovas-
cular status. While prior studies of hypothyroidism and mor-
tality have shown mixed findings, there has been a tendency
toward positive versus negative studies among cohorts of
higher versus low-to-average cardiovascular risk (6,8,13–
15,22). Furthermore, NHANES III data have shown that the
hypothyroidism–mortality association was dependent on
participants’ self-reported CHF status (6). Given the short-
term effects that thyroid hormone perturbations may have
upon health status (e.g., arrhythmia and systolic and dia-
stolic function), a decision was made to examine hospitali-
zation risk as an equally relevant outcome. In light of the high
healthcare costs and resource utilization associated with hos-
pitalization, as well as broad-scale efforts at the governmental
and policy-level to reduce inpatient admissions (particularly
30-day admissions for heart failure andmyocardial infarction),
further studies are needed to determine whether correction of
thyroid dysfunction may reduce hospitalization risk in high
cardiovascular risk populations (23–28).
The findings suggest a decreased risk of hospitalization
among those <60 years old, and hypothyroidism was asso-
ciated with a significantly decreased risk of hospitalization. It
is possible that this observation may be due to the fact that
symptoms of hypothyroidism are less pronounced in younger
individuals, and thus this group would present to an emer-
gency room less often. In contrast, we did not observe a
differential relationship between hypothyroidism and hospi-
talization risk on the basis of race or ethnicity in this diverse
Southern California–based cohort. The findings contrast with
those of an earlier NHANES III study showing a differential
association between hypothyroidism and mortality risk
among black versus non-black participants. It is possible that
these distinctions across studies may be explained by het-
erogeneous study populations, disparate short- versus long-
term effects of hypothyroidism upon health status, and dif-
ferential care in university- versus community-based settings
(24–30). Future studies are needed to explore whether the
prognostic implications of thyroid dysfunction differ ac-
cording to racial/ethnic background, as well as their potential
underpinnings (e.g., genetic/biologic, geographic, sociocul-
tural, and economic factors).
The strengths of this study include its examination of a
large, racially/ethnically diverse cohort with detailed longitu-
dinal data on comorbidities, laboratory tests, medications, and
hospitalization risk; definition of cardiovascular risk using
objective measures (i.e., ICD-9 codes and cardiovascular
medication prescription data as opposed to self-reported health
status); and rigorous analytic approaches, including compre-
hensive adjustment for potential confounders of the hypothy-
roidism–hospitalization risk association and competing risk
Table 3. Association Between Hypothyroidism with Hospitalization Risk, Stratified by Demographics
# of
Events
Risk
Time
Unadjusted Adjusted
Adjusted (including
Amiodarone)
HR [CI] p HR [CI] p HR [CI] p
Age, years
<60 19,384 5.76 0.94 [0.93–0.96] <0.001 0.89 [0.85–0.94] <0.001 0.92 [0.89–0.94] <0.001
‡60 33,472 5.43 1.14 [1.12–1.17] 1.05 [0.99–1.11] 1.12 [1.10–1.14]
Sex
Male 19,089 5.48 1.14 [1.12–1.16] 0.06 0.99 [0.93–1.06] 0.28 1.16 [1.13–1.19] 0.11
Female 33,767 5.73 0.94 [0.92–0.96] 0.94 [0.90–0.99] 0.84 [0.82–0.86]
Race
Black 4778 5.71 0.96 [0.93–1.01] 0.07 0.89 [0.75–1.07] 0.57 0.99 [0.98–1.0] 0.66
Non-black 48,078 5.64 1.03 [0.98–1.07] 0.96 [0.92–1.00] 1.01 [0.97–1.1]
Ethnicity
Hispanic 4557 5.74 0.98 [0.95–1.01] 0.26 0.96 [0.85–1.09] 0.83 0.98 [0.94–1.02] 0.36
Non-Hispanic 48,299 5.63 1.14 [1.12–1.16] 0.96 [0.92–1.00] 1.06 [0.98–1.14]
Analyses adjusted for age, sex, race, ethnicity, body mass index, diabetes, hypertension, hyperlipidemia, congestive heart failure,
coronary artery disease, and cerebrovascular disease.
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methods. However, several limitations of the study bear
mention. First, the definition of hypothyroidism did not addi-
tionally consider triiodothyronine (T3) and thyroxine (T4)
levels due to sparse measurements concurrent with TSH.
However, it should be noted that compared to TSH as the most
sensitive and specific singlemetric of thyroid status, T3 and T4
levels are more likely to be influenced by mild to moderate
nonthyroidal illness, respectively, and low TSH levels may be
observed with severe, critical illness, TSH levels at this
spectrumwere not considered in the analyses (31–37). Second,
it is also possible that the study did not capture thyroid func-
tional tests and hospitalizations that occurred outside of the
university-based center. However, misclassification on this
basis would not be expected to differ according to exposure
status (i.e., non-differential misclassification), thus rendering
the findings to be conservative. Third, data on cause-specific
hospitalization were lacking to elucidate potential pathways
between thyroid status and hospitalization risk. Fourth, the
study examined TSH levels measured at a single point in time
(i.e., baseline) in lieu of repeated measurements. However,
longitudinal examination of TSH trends in the general popu-
lation has shown minimal variations over time (i.e., variation
of 0.5mIU/L when measured monthly over a one-year period)
(29,30). In addition, the most common scenario for TSH
fluctuation would be TSH falling in response to systemic ill-
ness, in which this potential bias should favor patients with
higher TSH levels and render conservative the observed as-
sociation between hypothyroidism and hospitalization risk.
Lastly, as with all observational studies, the possibility of re-
sidual confounding cannot be excluded.
In summary, this study has shown for the first time that
hypothyroidism is associated with higher risk of hospitali-
zation among patients with underlying cardiovascular disease
(e.g., CHF, CAD, and CVD). Future studies are needed to
corroborate findings, elucidate underlying mechanisms, and
determine whether correction of TSH perturbations with
thyroid hormone replacement therapy ameliorates hospitali-
zation risk.
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